CanSino (CASBF): This adenovirus vector vaccine (Ad5) is said to be submitting data to Mexico shortly, presumably for regulatory approval. Trials have been underway there, as well as in Pakistan, Chile, and other countries. No efficacy or safety data have been reported publicly, however.
Gamaleya Research Institute: This two-adenovirus-vector two-dose vaccine has made some news as well. Earlier this month, a press release from Gamaleya Research Institute (GRI) said that the vaccine was 91% effective, based on a trial with over 17,000 vaccinated patients and over 5600 controls. The release also says that a full paper is in the works, to be published in a leading journal, and I very much look forward to that. It appears that the vaccine is now being shipped to Belarus, Argentina and Hungary, but Reuters reports that the Argentina shipment is for only the first dose, which is the easier of the two different adenovirus vectors to manufacture. Nothing on the other countries as yet, but the Hungarian shipment was quite small (6,000 doses), which tells you that it's more in press release territory anyway. It's unclear what's going on - Reuters had a source saying that the Argentine shipment was excess production from the manufacture of the first shot, and that they're still catching up on the second. I have seen no reliable figures on the protection offered by just that first shot - the director of the GRI has said, though, that immunity from the first shot lasts only 3-4 months.
Meanwhile, the earlier-reported collaboration between GRI and AstraZeneca seems to be real - a clinical trial has been registered. I'm quite curious to see how this is going to go, and whether it will produce results in time to make any sort of impact.
AI
Market Data 
Markets 
